Overseas Registration of Medical Imaging Devices: Requirements for Risk Management Files

Risk Management Documentation for Overseas Registration of Imaging Devices

When registering imaging devices overseas, the risk management file is a core component of the technical documentation. Manufacturers must first confirm the regulatory classification of the device in the target country. Most GHWP member states apply risk-based classification rules; imaging devices are typically Class II or III. A risk management report aligned with IMDRF or local guidance is required. The risk management process should be based on ISO 14971 and linked to the ISO 13485 quality management system, producing records such as risk analysis, risk evaluation, risk control measures, and residual risk evaluation. For registration in different countries, the risk management file can be localized from a core set of reusable content, adding local standards, language, and epidemiological data. The local agent or authorized representative must have clear responsibilities for file maintenance and updates. Common mistakes include disconnection between the risk management report and clinical evaluation, poor version control, failure to address use environment and interface risks, and not feeding post-market risk data back into the registration file. Therefore, manufacturers must establish a complete chain of evidence covering the entire lifecycle and supporting future changes and renewals.

Published: 2026-08-22 09:40 | Updated: 2026-08-22 09:40

Based on AIMEILI registration practice question bank, medical device international registration knowledge base, and public regulatory information. Specific projects should follow the latest requirements of the target country's regulatory authorities and the product's technical documentation.

Scope and Core Issues

Imaging devices include X-ray machines, CT, MRI, and ultrasound diagnostic systems. In overseas registration, regulatory scrutiny of risk management files has increased year by year. The scope covers not only initial registration but also change registration, certificate renewal, and post-market surveillance. The core question for manufacturers is how to transform internal risk management processes into a complete chain of evidence within the registration file while meeting local regulatory requirements.

Many manufacturers mistakenly believe that the risk management file is just a single risk analysis report or that having ISO 14971 certification is sufficient. In fact, regulators examine whether the risk management process runs through the entire product lifecycle and is consistent with other technical files. Ignoring differences in applicable scenarios leads to frequent deficiencies and extended registration timelines.

Registration Decision Logic

Determine Regulatory Classification

Manufacturers must first determine whether the target country regulates imaging devices as medical devices and at what risk level. GHWP member states generally reference IMDRF classification rules, but there are differences. For example, some ASEAN countries classify diagnostic X-ray equipment as moderate risk, while CT and MRI may be high risk.

Identify Registration Pathway and Applicant

Most countries require a local registrant or license holder to submit the application. Overseas manufacturers must appoint a local agent or authorized representative. The risk management file should support the local agent in fulfilling submission and communication duties.

Assess Reusability of Existing Documents

If the product already has NMPA registration, CE certification, or FDA 510(k), the risk management documents, clinical evaluation data, and test reports from those filings can serve as a foundation. However, local standard requirements and language versions must be checked.

Define Localization Needs

The intended use, target population, environmental conditions, and warning information in the risk management file must align with local instructions for use and labeling. For markets requiring local clinical or epidemiological data, plan ahead.

Documentation and Evidence

The core of the risk management file is the risk management report, but regulators typically require systematic risk management documentation. Evidence includes: risk analysis plan, risk analysis (intended use identification, hazard identification, risk estimation), risk evaluation, risk control measures and their verification, residual risk evaluation, risk management report, and feedback from production and post-market phases.

For imaging devices, special attention must be given to hazard sources such as ionizing radiation dose to patients and operators, effects of magnetic fields on implanted devices, thermal and mechanical effects from ultrasound output, electrical safety, and electromagnetic compatibility. These hazards must be analyzed individually in the risk management report and linked to safety standards and performance test results.

Manufacturers should provide evidence of a risk management process that follows ISO 14971 and is consistent with ISO 13485 quality system documentation. The risk management file should cross-reference clinical evaluation (or clinical data) to demonstrate how the effectiveness of risk control measures is supported by clinical information and performance testing.

If the target country is a GHWP member or references IMDRF, the risk management file must also demonstrate conformity with essential principles for safety and performance. A risk management matrix or essential requirements checklist is recommended to ensure nothing is omitted.

In practice, risk management files often need to be submitted in the local language. Manufacturers should retain both original and translated versions and ensure terminology consistency. The local agent should be able to explain the logic of the risk management report and its update history.

Common Errors

• Risk management report is treated as a standalone document, not linked to risk analysis, verification records, or post-market data, causing a broken chain of evidence.
• Copying risk management files from other markets without identifying local usage conditions and standard differences, such as local grid voltage or user qualification requirements.
• Inadequate analysis of special hazards of imaging devices, such as focusing only on electrical safety and ignoring radiation dose, image quality, or misdiagnosis risk.
• Inconsistency between intended use in the risk management document and labels/instructions, or missing contraindications and warning information.
• Failure to define the local agent's responsibilities for maintaining, updating, and submitting the risk management file, causing delays in responding to regulatory queries.
• Post-market surveillance plan is only a formality, without effective adverse event feedback and risk management file update mechanisms.

Manufacturer’s Readiness Checklist

• Confirm the regulatory classification, registration pathway, and applicant requirements for imaging devices in the target country.
• Appoint or confirm a local agent or authorized representative and sign a service and responsibility agreement.
• Establish a risk management process compliant with ISO 14971 and ensure file control under the quality management system.
• Collect and organize existing registration materials and test reports from markets such as NMPA, CE, and FDA.
• Identify specific local standards and assess gaps, including electrical safety, radiation safety, EMC, and usability standards.
• Complete localization of the risk management report, including translation and appropriate adjustment of intended use.
• Prepare cross-references between the risk management report and clinical evaluation, biocompatibility, and performance testing.
• Develop a post-market surveillance plan and adverse event reporting procedures, with clear triggers for updating the risk management report.
• Confirm the version control and change notification mechanism for the risk management file with the local agent.

AIMEILI Regulatory Interpretation and Business Impact

Manufacturers often misjudge the risk management file as an optional part of the registration dossier or assume that holding an ISO 14971 certificate is sufficient. Based on our experience, regulators look for genuine implementation of the risk management process, not just form. Another common misconception is treating the risk management report as a static document, ignoring post-market data that continuously validates risk control measures.

At the project outset, manufacturers should perform a regulatory gap analysis of the target market to determine the classification of the imaging device, then organize the preparation of the risk management file. Do not start by translating existing documents; first confirm whether the core content is applicable.

Reusable materials include: the ISO 14971 risk management report framework, existing hazard analysis, electrical safety and EMC test data, clinical literature, and published clinical evaluation data. Content that must be localized includes: intended use statements, environmental conditions, warnings and contraindications, language translation, and risk assessments based on local epidemiology or operating practices.

The local agent’s role extends beyond submission; they bear the legal responsibility for communicating with regulators, explaining technical files, and updating files. If the certificate is held by the local agent, manufacturers should contractually ensure the agent fulfills change and renewal obligations while retaining control over the risk management file content.

For multi-country registrations, we recommend establishing a “master risk management file” based on ISO 14971, adding a “country annex” for each market to describe local differences. This approach avoids rework and repeated submissions due to deficiencies, improving registration efficiency.

Frequently Asked Questions

Q: Should the risk management file be submitted separately or as part of the technical documentation? Most countries accept the risk management report as part of the technical documentation; some may require a separate risk management summary form. We recommend following the required table of contents and ensuring cross-references between risk analysis and the essential requirements checklist.

Q: If the product is already CE or FDA registered, can the original risk management file be used directly? Core content can be reused, but regulatory differences and language requirements must be assessed. If local standards or intended use differ, modify the risk management report and explain the differences. Direct copying may lead to deficiencies.

Q: How should the risk management file be updated after market launch? Manufacturers should establish a post-market surveillance procedure to collect adverse events, complaints, and literature data, periodically review risks, and update the risk management report based on the review results. The updated file should be notified to the local agent and submitted at certificate renewal.

Q: Is the local agent responsible for the authenticity of the risk management file? In most countries, the local agent is the registration applicant and responsible for the legal authenticity of the submitted documents. We recommend a written agreement with the agent to define content responsibility and update obligations, while retaining your own quality system evidence.

Related Reading and Boundaries

Editor: AIMEILI Regulatory Editorial Department | Professional Review: AIMEILI Medical Device International Registration Project Team | Source Principle: Official regulatory bodies, international organizations, standards bodies, and public regulatory materials are preferred; industry media and project experience are used only for supplementary judgment.

Applicability: This article is for preliminary understanding, document preparation, and project planning. It does not replace formal requirements from target country regulators, test conclusions, or legal advice.